These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 32475025)

  • 1. Prevalence of Rheumatoid Arthritis and Drug Dispensing Patterns Among Medicaid and Medicaid-Medicare Dually Eligible Beneficiaries in Puerto Rico.
    Hernández-Muñoz JJ; Wei W; Sierra-Zorita R
    Arthritis Care Res (Hoboken); 2021 Feb; 73(2):199-206. PubMed ID: 32475025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data.
    Steffen A; Holstiege J; Klimke K; Akmatov MK; Bätzing J
    Rheumatol Int; 2018 Nov; 38(11):2111-2120. PubMed ID: 30306254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the prevalence and incidence of rheumatoid arthritis in Korea and an analysis of medical care and drug utilization.
    Won S; Cho SK; Kim D; Han M; Lee J; Jang EJ; Sung YK; Bae SC
    Rheumatol Int; 2018 Apr; 38(4):649-656. PubMed ID: 29302803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receipt of glucocorticoid monotherapy among Medicare beneficiaries with rheumatoid arthritis.
    Yazdany J; Tonner C; Schmajuk G; Lin GA; Trivedi AN
    Arthritis Care Res (Hoboken); 2014 Oct; 66(10):1447-55. PubMed ID: 25244314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use and Spending for Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among US Medicare Beneficiaries.
    Yazdany J; Tonner C; Schmajuk G
    Arthritis Care Res (Hoboken); 2015 Sep; 67(9):1210-1218. PubMed ID: 25776035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage.
    Tatangelo M; Tomlinson G; Paterson JM; Ahluwalia V; Kopp A; Gomes T; Bansback N; Bombardier C
    JAMA Netw Open; 2019 Dec; 2(12):e1917053. PubMed ID: 31808927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wide difference in biologics usage and expenditure for the treatment of patients with rheumatoid arthritis in each prefecture in Japan analyzed using "National Database of Health Insurance Claims and Specific Health Checkups of Japan".
    Kamata Y; Minota S
    Rheumatol Int; 2018 Apr; 38(4):663-668. PubMed ID: 29204683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variability in Glucocorticoid Prescribing for Rheumatoid Arthritis and the Influence of Provider Preference on Long-Term Use of Glucocorticoids.
    George MD; Baker JF; Wallace B; Chen L; Wu Q; Xie F; Yun H; Curtis JR
    Arthritis Care Res (Hoboken); 2021 Nov; 73(11):1597-1605. PubMed ID: 32702188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Geographic Variation in the Quality and Cost of Care for Patients with Rheumatoid Arthritis.
    Shafrin J; Ganguli A; Gonzalez YS; Shim JJ; Seabury SA
    J Manag Care Spec Pharm; 2016 Dec; 22(12):1472-1481. PubMed ID: 27882832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.
    Jin Y; Desai RJ; Liu J; Choi NK; Kim SC
    Arthritis Res Ther; 2017 Jul; 19(1):159. PubMed ID: 28679392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in the use of disease modifying antirheumatic medications in rheumatoid arthritis, 1980-1995: results from the National Ambulatory Medical Care Surveys.
    Ward MM
    J Rheumatol; 1999 Mar; 26(3):546-50. PubMed ID: 10090160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Out-of-Pocket Costs on Prescription Fills Among New Initiators of Biologic Therapies for Rheumatoid Arthritis.
    Hopson S; Saverno K; Liu LZ; AL-Sabbagh A; Orazem J; Costantino ME; Pasquale MK
    J Manag Care Spec Pharm; 2016 Feb; 22(2):122-30. PubMed ID: 27015251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health Care Effect of Disease-Modifying Antirheumatic Drug Use on Patients with Rheumatoid Arthritis.
    Boytsov NN; Bhattacharya R; Saverno K; Dixon L; Abbott PL; Zhang X; Gaich CL; Nair R
    J Manag Care Spec Pharm; 2019 Aug; 25(8):879-887. PubMed ID: 31347977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease-modifying antirheumatic drug initiation among patients newly diagnosed with rheumatoid arthritis.
    Bonafede M; Johnson BH; Shah N; Harrison DJ; Tang D; Stolshek BS
    Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP279-SP285. PubMed ID: 30020740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study.
    Ingrasciotta Y; Jin Y; Foti SS; Landon JE; Tari M; Mattace-Raso F; Kim SC; Trifirò G
    Clin Rheumatol; 2023 Apr; 42(4):1047-1059. PubMed ID: 36534353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization and costs of medical services and prescription medications for rheumatoid arthritis among recipients covered by a state Medicaid program: a retrospective, cross-sectional, descriptive, database analysis.
    Khanna R; Smith MJ
    Clin Ther; 2007 Nov; 29(11):2456-67. PubMed ID: 18158087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology and Treatment of New-Onset and Established Rheumatoid Arthritis in an Insured US Population.
    Crane MM; Juneja M; Allen J; Kurrasch RH; Chu ME; Quattrocchi E; Manson SC; Chang DJ
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1646-55. PubMed ID: 26097059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delay in initiation of DMARD or anti-inflammatory therapy in patients newly diagnosed with rheumatoid arthritis: An analysis of United States Military Health System TRICARE beneficiaries.
    Kimsey L; Weissman JS; Patel A; Drew A; Koehlmoos T; Sparks JA
    Semin Arthritis Rheum; 2019 Apr; 48(5):821-827. PubMed ID: 30190154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.